All News

Empower Pharmacy founder and CEO Shaun Noorian argues that declining patient engagement across demographics is a failure of system design not patient behavior.

The Troutman Pepper Locke senior associate discusses strategies for pharma and biotech companies to implement ahead of the July 31st tariff deadlines.

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 billion patent cliff, the pricing pressures of the Inflation Reduction Act, and shifting regulatory dynamics.

Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs.

Ryan Last, senior associate at Troutman Pepper Locke explains how existing regulations and potential foreign countermeasures have a significant impact on reshoring efforts.

In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including Alzheimer's candidate ACD856, the Medicare GLP-1 Bridge launches today, giving eligible Medicare Part D beneficiaries access to Wegovy, Foundayo, and Zepbound for a $50 monthly copay through the end of 2027, and Pharmaceutical Executive speaks with Ryan Last of Troutman Pepper Locke on the limits of targeted pharmaceutical tariffs as a reshoring tool and why thin margins on many generic products complicate the policy's effectiveness.

Novo Nordisk has launched the Medicare GLP-1 Bridge, making Wegovy available to eligible Medicare beneficiaries for $50 a month through the end of 2027, giving millions of older adults with obesity a structured pathway to the FDA-approved weight management drug.

AlzeCure Pharma has licensed its NeuroRestore platform and lead CNS candidate ACD856 to QuantumCell ApS, following positive Phase Ib safety and pharmacokinetic data.

Troutman Pepper Locke senior associate Ryan Last explains how thin margins on certain product will impact the effectiveness of tariffs.

Ryan Last, senior associate at Troutman Pepper Locke, details the key steps that pharma companies must make before the July 31st deadline hits.

A U.S. House committee has launched national security investigations into Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb over their clinical trial operations in China, seeking answers by July 17 on data protection, military hospital ties, and trial sites in Xinjiang.

FDA selected seven companies to participate in its new PreCheck Pilot Program, offering earlier regulatory engagement and expedited facility review to incentivize domestic drug manufacturing.

In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, Krista Pinto of Eversana argues that fully staffed pharma field teams are still missing revenue targets because the traditional deployment model itself needs to evolve, and EMA's CHMP issues a positive opinion recommending approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia across all lines of therapy in the European Union.

Zymeworks and Ipsen each announced acquisitions this week, with Zymeworks paying roughly $929 million for Theravance Biopharma to gain commercial COPD royalties and tax assets, and Ipsen committing up to $1.75 billion for Kartos Therapeutics to add navtemadlin.

Krista Pinto, EVERSANA’s president of deployment solutions, shares her perspective on why traditional field team models need to evolve to support future commercial success.

The decision was made based on the results of the BRUIN CLL-313 clinical study.

Healthspan is merging from obscure academic jargon as a potent consumer driver, reshaping how people think about aging and redefining pharma’s role in that process.

New data from ADA 2026 reveal that assumptions around age, weight, and gestational history are leaving too many T1D patients misclassified — and the clinical consequences are preventable.

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic triple-negative breast cancer — as both a monotherapy and in combination with Keytruda — marking the first new backbone therapy option for this aggressive disease in more than two decades, Novartis announces a $105 million collaborative agreement with Antares Therapeutics to jointly discover and develop first-in-class precision medicines in oncology and other serious diseases, with potential milestones totaling $1.8 billion, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on the real-world benefits and persistent challenges of operating as a fully domestic manufacturer in an era of tariffs and supply chain pressure.

Jeff Talbot of Roseman University of Health Sciences discusses how Las Vegas is positioning itself as a growing life sciences hub by offering cost-effective laboratory space, access to capital, and a flexible environment for biotech startups and emerging companies.

Novartis will fund Antares’ development of first-in-class precision medicines in cancer and other serious diseases.

Once a niche pilot, direct-to-patient drug distribution is now a defining strategic priority, with manufacturers building the right infrastructure standing to capture margin, data, and patient relationships that used to belong to intermediaries.

Aprecia’s president and COO discusses the impact 3D printing technology is having on drug development, along with the benefits and challenges of being a company that is 100-percent US-based for its manufacturing.

The FDA has approved Trodelvy (sacituzumab govitecan-hziy) for first-line treatment of metastatic triple-negative breast cancer as both a monotherapy and in combination with pembrolizumab, supported by Phase 3 data from the ASCENT-03 and ASCENT-04 trials.

The FDA has approved Ibrance (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to advance targets selected by Lilly, building on a prior partnership between the two companies, Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on how the company's 3D printing technology enables real-time quality monitoring and rapid iteration to accelerate drug production, and life sciences industry advisor Partha Anbil examines the economics of the 340B Drug Pricing Program — including the forces driving its record $81.4 billion in 2024 purchases, the legal battles over manufacturer restrictions and rebate models, and what it all means strategically for pharmaceutical manufacturers in 2026.

Abbisko will utilize its drug development platform and R&D ecosystem to develop drug targets determined by Lilly.

Aprecia’s president and COO discusses the benefits of using 3D printing technology to quickly produce high quality drug tablet in a variety of dosages.